These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1012 related items for PubMed ID: 27384161

  • 1. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK.
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [Abstract] [Full Text] [Related]

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
    Roh TH, Park HH, Kang SG, Moon JH, Kim EH, Hong CK, Ahn SS, Choi HJ, Cho J, Kim SH, Lee SK, Kim DS, Kim SH, Suh CO, Lee KS, Chang JH.
    Medicine (Baltimore); 2017 Jul 01; 96(27):e7422. PubMed ID: 28682902
    [Abstract] [Full Text] [Related]

  • 6. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.
    Cancer; 2012 Sep 15; 118(18):4545-54. PubMed ID: 22359215
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.
    J Neurooncol; 2015 Nov 15; 125(2):359-67. PubMed ID: 26423801
    [Abstract] [Full Text] [Related]

  • 9. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.
    J Clin Oncol; 2010 Jun 01; 28(16):2712-8. PubMed ID: 20439646
    [Abstract] [Full Text] [Related]

  • 10. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A, Bock HC, Reifenberger G, Brück W, Giese A.
    Acta Neurochir (Wien); 2013 Mar 01; 155(3):429-35. PubMed ID: 23254891
    [Abstract] [Full Text] [Related]

  • 11. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B.
    Int J Radiat Oncol Biol Phys; 2017 Mar 01; 97(3):487-494. PubMed ID: 28011051
    [Abstract] [Full Text] [Related]

  • 12. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.
    J Neurooncol; 2011 Apr 01; 102(2):311-6. PubMed ID: 20686820
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG, Khedr RA, El-Shorbagy SH.
    J Egypt Natl Canc Inst; 2016 Mar 01; 28(1):23-30. PubMed ID: 26682634
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):1066-74. PubMed ID: 20932651
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.
    Clin Neurol Neurosurg; 2015 May 15; 132():1-8. PubMed ID: 25723791
    [Abstract] [Full Text] [Related]

  • 16. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.
    Radiat Oncol; 2015 Oct 31; 10():222. PubMed ID: 26520780
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):655-60. PubMed ID: 22483738
    [Abstract] [Full Text] [Related]

  • 18. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, Narita Y.
    Radiat Oncol; 2019 Nov 12; 14(1):200. PubMed ID: 31718669
    [Abstract] [Full Text] [Related]

  • 19. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.
    Br J Neurosurg; 2013 Aug 12; 27(4):430-5. PubMed ID: 23418781
    [Abstract] [Full Text] [Related]

  • 20. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM.
    Int J Radiat Oncol Biol Phys; 2015 Jan 01; 91(1):109-15. PubMed ID: 25442339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.